You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Follow-up After Primary Therapy for Endometrial Cancer

Version: 2 ID: 4-9 Jun 2017
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
M. Fung-Kee-Fung, J. Dodge, L. Elit, H. Lukka, A. Chambers, T. Oliver , Gynecology Cancer Disease Site Group

Patient Population

Women without evidence of disease after primary potentially curative treatment for any stage of endometrial cancer comprise the target population. Of particular interest are outcomes from follow-up strategies reported for patients at a lower risk of recurrence (i.e., stage IA or IB, grade 1 or 2) and those at a higher risk of recurrence (i.e., stage IA or IB, grade 3, or stage IC or advanced stage).

Research Question(s)

What is the most appropriate strategy for the follow-up of patients with endometrial cancer who are clinically disease free after receiving potentially curative primary treatment? Specifically, do differences in follow-up intervals, diagnostic interventions, clinical setting, or specialty influence patient outcomes related to local or distant recurrence, survival, or quality of life?

pdf download Summary (PDF) (187.29 KB)
pdf download Full Report (PDF) (804.06 KB)